Enhanced purification of adeno-associated virus for more effective removal of contaminating DNA
The use of positively charged surfaces and tangential flow filtration with DNase treatment addresses the challenge of low DNA removal in AAV purification, achieving high-purity AAV preparations with enhanced concentration capabilities.
Patent Information
- Application Number
- JP2022574843
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-06-05
- Filing Date
- 2021-06-04
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-06-04
AI Technical Summary
Existing methods for purifying adeno-associated virus (AAV) preparations are inadequate in reducing contaminating DNA to very low levels, leading to safety concerns and inefficiencies in concentration and filtration processes.
A method involving the use of positively charged surfaces to bind and remove DNA, followed by tangential flow filtration (TFF) and DNase treatment, with optional chromatography steps to achieve high purity AAV.
The method effectively reduces contaminating DNA to low levels, allowing concentration factors of 10-20 times and enhances the purity of AAV preparations, suitable for clinical and research applications.
Smart Images

Figure 0007586936000001 
Figure 0007586936000002 
Figure 0007586936000003
Abstract
Description
[Technical field]
[0001] The present invention discloses a method for reducing the contaminating DNA content of a preparation containing AAV capsids and contaminating DNA. [Background technology]
[0002] Adeno-associated virus (AAV) is widely used as a delivery vehicle for therapeutic DNA in the field of human gene therapy. The virus is produced by cell culture techniques, most commonly using mammalian or insect host cells. The cell culture is engineered so that the desired therapeutic DNA plasmid is present inside the AAV capsid. The cell culture is harvested and the DNA-containing AAV capsid is purified by standard chromatographic methods such as affinity chromatography, ion exchange chromatography, and hydrophobic interaction chromatography.
[0003] As with any therapeutic that can be administered to humans, contaminating DNA must be reduced to very low levels to ensure safety. This has proven more difficult than expected. Recently developed analytical techniques suggest that this difficulty may result from residual DNA bound to the outside of the AAV capsid. This is perhaps not surprising, since AAV capsids are known to bind strongly to cation exchangers. Strong binding to cation exchangers indicates that the exterior of the AAV capsid carries a strong positive charge. DNA is electronegative and binds strongly to positively charged surfaces. Whatever the mechanism, these findings highlight the difficulty of removing DNA.
[0004] Currently, the industry standard is to simply add DNase enzyme to AAV harvests. Unfortunately, this method only reduces DNA slightly and does not solve the problem of reducing contaminating DNA to very low levels. This has the side benefit of improving the filterability of the harvest from hopeless to possible, but filter clogging is still a common problem, requiring excessive filtration media and causing loss of AAV capsids. Also, processing methods such as tangential flow filtration do not allow the harvest to be concentrated to any significant extent. Concentration factors of up to 2-fold may be possible, but rarely more than that.
[0005] International Publication WO02 / 12455 A1 discloses a method for large-scale purification of recombinant AAV (rAAV) virions produced in the absence of infectious adenovirus. Preferably, rAAV is produced in a host cell line via triple transfection with an accessory function vector, an AAV vector, and an AAV helper vector. The method includes preparing a lysate from the host cell line and subjecting the lysate to various combinations of ion exchange and / or affinity chromatography media. The affinity chromatography media is an antibody having binding affinity for AAV receptors or AAV, e.g., heparin sulfate. Various cation and anion exchange media are contemplated. In certain embodiments, an optional purification step may be included, such as filtering the lysate through one or more filters or treating the lysate with a nuclease.
[0006] International Publication WO2010 / 148143 A1 discloses a method for purifying recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer, particularly gene therapy or vaccination. The recombinant AAV vectors are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper viruses, and medium components.
[0007] International Publication WO03 / 097797 A2 discloses a process for purifying viral particles, particularly recombinant adenoviral vector particles. The process relies on various combinations of cell lysis, detergent-based precipitation of host cell contaminants away from the virus, depth filtration or centrifugation, ultrafiltration, nuclease digestion and chromatography to robustly and economically produce a high purity product. The process consistently produces levels of contaminating DNA below undetectable levels.
[0008] International Publication WO2019 / 006390 A1 discloses a method for purifying, producing and preparing recombinant adeno-associated virus (rAAV) vector particles, comprising at least two column chromatography steps, such as cation exchange chromatography, anion exchange chromatography, size exclusion chromatography, and / or AAV affinity chromatography, either alone or in combination, in any order.
[0009] All documents cited herein are incorporated by reference to the extent they do not contradict the teachings presented herein. Summary of the Invention [Problem to be solved by the invention]
[0010] We have developed a novel method for AAV purification, specifically for the reduction of DNA contamination, that is surprisingly enhanced. Cell culture harvests or lysates are exposed to a positively charged surface(s) to bind DNA that is not bound to AAV particles. Treatment with the positively charged surface(s) achieves an initial reduction in DNA and facilitates tangential flow filtration (TFF) to an extent that allows for concentration factors of 10-20 or more. The ability to perform solid-phase extraction with a positively charged surface is surprising, given that DNase treatment of cell harvests or lysates does not provide such improved filterability. [Means for solving the problem]
[0011] According to the method of the invention, the contaminating DNA content in a preparation comprising AAV capsids and contaminating DNA is reduced, the method comprising the steps of: (a) performing extraction of DNA using a solid phase carrying a positive charge on its surface to obtain a first fraction, wherein the solid phase is contacted with the preparation at pH 7.0±1.0 and a salt concentration of 10 mM to 200 mM; (b) diafiltering the first fraction by a first tangential flow filtration to obtain a second fraction; (c) treating the second fraction with DNAse; (d) diafiltering the DNAse-treated second fraction obtained in step (c) into a buffer having a pH of 7.0±1.0 and a salt concentration of 10 mM to 20 mM by a second tangential flow filtration to obtain a third fraction; and Optionally, (e) concentrating the third fraction by tangential flow filtration prior to complementary chromatography.
[0012] In one embodiment of the method of the present invention, the solid phase may be in the form of loose bulk particles or a flow-through device.
[0013] In another embodiment of the process of the invention, tangential flow filtration may be performed using a membrane selected from the group consisting of hollow-fiber membranes, such as single hollow-fiber membranes or bundled membranes, or flat membranes, such as single membranes or stacked or rolled membranes.
[0014] In yet another embodiment of the method of the present invention, the first filtration may be carried out in a buffer formulated to promote DNA digestion by DNase.
[0015] In yet another embodiment of the method of the present invention, the porosity of the tangential flow filtration membrane may be in the range of 10 kDa to 300 kDa, 30 kDa to 300 kDa, 60 kDa to 300 kDa, 100 kDa to 300 kDa, 200 kDa to 300 kDa, or 250 kDa to 300 kDa, and preferably has a molecular weight cutoff of 100 kDa or more.
[0016] In further embodiments of the methods of the invention, the preparation comprising AAV capsids and contaminating DNA may contain AAV particles selected from the group consisting of AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or other serotypes, such as recombinant serotypes having characteristics of two or more serotypes.
[0017] In yet another embodiment of the method of the present invention, the fraction obtainable after step (d) or step (e) may be further proceeded according to the following options (i) to (iii): Option (i) cation exchange chromatography; Option (ii) affinity chromatography, or Option (iii) Anion exchange chromatography.
[0018] In yet another embodiment of the second aspect of the method of the invention, in purification step (i), the fraction of step (d) or (e) is loaded onto a cation exchange chromatography material at pH 4-6 (in particular at about pH 5) followed by re-equilibrating the cation exchange chromatography material to about pH 3.5±0.5; performing elution using a salt gradient; and Then, anion exchange chromatography is performed. This process, for example, results in clinical quality AAV.
[0019] In another embodiment of the method of the invention, in purification step (ii), the fraction from step (d) or (e) is loaded onto an affinity chromatography material and, after elution, subjected to an anion exchange chromatography treatment, which process, for example, yields purified AAV.
[0020] In yet another embodiment of the method of the invention, in purification step (iii), the fraction from step (d) or (e) is subjected to an anion exchange chromatography column. This process can, for example, yield research grade AAV. [Brief description of the drawings]
[0021] [Figure 1] FIG. 1 is a diagram showing an overview of the method of the present invention. [Diagram 2] FIG. 2 is a cation exchange chromatography diagram illustrating the application of the method of the present invention. [Diagram 3] FIG. 3 shows analytical reducing SDS-polyacrylamide gel electrophoresis (PAGE) comparing standard conditions with those of the method of the invention. [Figure 4] FIG. 4 shows the capture of AAV from cell lysates by affinity chromatography. [Diagram 5]FIG. 5 shows analytical reducing SDS-PAGE of fractions shown from the affinity chromatograms shown in FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] The embodiments of the present invention will now be described in more detail by way of example using AAV as the entity to be purified, similarly other entities may be purified in a similar manner as would be readily recognized by one of ordinary skill in the art upon reading and comprehending this disclosure.
[0023] Those skilled in the art will recognize that DNA can alternatively be removed from the process solution by adding a positively charged soluble polymer instead of a positively charged solid phase material. This is highly unstable from a clinical safety point of view, and may alter the biological behavior of purified capsids in vitro, leading to misleading results, not representative of AAV, and caused by the positively charged polymer. It may also have the effect of protecting some DNA from lysis by DNase enzymes. DNA is known to actively bind to the outer surface of AAV capsids. If a positively charged polymer is added to a preparation containing such AAV capsids, the positively charged polymer may create a coating on the capsid-exterior-associated DNA. Strong binding between DNA and positively charged proteins is known to interfere with DNase enzymes. Positively charged polymers may do so to a greater extent. If the positively charged polymers remain associated with the AAV capsid after purification, they can then be eluted into in vitro samples or slowly released into living subjects, such as laboratory animals or humans. All positively charged polymers are chemical irritants and cause inflammation. Considering that the purified AAV capsids will ultimately be administered to people who are already sick, the inadvertent administration of known inflammatory substances represents an unnecessary and potentially significant risk. The present invention highlights the inventive nature of the innovation, as it provides a method for extracting DNA using a solid phase material that is completely removable from the AAV capsid preparation after processing.
[0024] The buffer for the concentrated TFF step is formulated to facilitate DNA digestion by the selected DNase enzyme in the subsequent process step. The selected DNase enzyme is added and incubated for an appropriate time, with two notable differences from routinely performed DNA lysis: (1) the ability to concentrate TFF allows for a smaller volume and therefore less enzyme; (2) removal of inhibitors and buffer exchange to optimal lysis conditions for the selected DNase enzyme can achieve a much more effective reduction than the standard method of simply adding it to a raw cell harvest or lysate.
[0025] It is advantageous for the porosity of the TFF membrane to be as large as possible while still retaining the capsid. Porosity will vary somewhat depending on the manufacturer and membrane material, but generally, membranes with a molecular weight cutoff of 250 kDa to 300 kDa are ideal. Lower MWCO values are less effective at removing contaminants, but still substantially reduce the contaminant content of the processed preparation. Overall, TFF membranes can be used with MWCO values of 10 kDa to 300 kDa, 30 kDa to 300 kDa, 60 kDa to 300 kDa, 100 kDa to 300 kDa, 200 kDa to 300 kDa, or 250 kDa to 300 kDa, with greater than 100 kDa being preferred.
[0026] TFF membranes are commercially available in a variety of physical shapes and sizes to accommodate different research and development (R&D), scale-up, and manufacturing needs. TFF membranes include flat membranes, either single or stacked or rolled; and hollow fibers, either single or bundled.
[0027] The technique of tangential flow filtration (TFF), as in the method of the present invention, is generally carried out in one or any combination of three principle modes. The first of these modes is concentration, the purpose of which is to remove excess fluid to make the subsequent processing operations more efficient. The second mode is diafiltration. During diafiltration, the original liquid, salts, sugars, and buffer components are filtered out and new fluids free of these components are introduced. This has the effect of "buffer exchanging" the fluid in which the sample is present, preparing it for further processing. The term diafiltration is a combination of two words: dialysis and filtration. The third mode is size-based purification. Concentration and diafiltration can be carried out using tangential flow filtration membranes with any porosity that retains the target substance, such as membranes with a molecular weight cutoff of 10 kDa or less. The use of TFF as a purification tool represents an extension of the use of large pore membranes to allow the removal of contaminating biomolecules, particularly those smaller than the target substance. Considering that the porosity must be small enough to retain the target substance, the membrane with the largest pores that meet this condition has the advantage of being able to remove the widest size range of contaminating biomolecules. In the present case, the AAV capsid is quite large in terms of the scale of biological products, so a membrane with very large pores, such as a molecular weight cutoff of up to 300 kDa, can be used to remove most proteins and other biomolecules. The smaller the contaminating biomolecules, the more effectively they can be removed. This makes it particularly suitable for the removal of DNase enzymes after DNA lysis and the removal of histone proteins released from host cell DNA due to the lysis of previously bound DNA.
[0028] Many DNase enzymes are commercially available, but each requires its own conditions to achieve the best results. Preliminary experimental data indicate that so-called salt-tolerant DNase enzymes may provide superior results. Some DNase enzymes also dissolve RNA, which may be useful to the extent that RNA stabilizes large DNA heteroaggregates. If the DNase enzyme lacks this ability, RNase enzyme may be added to the DNase enzyme. However, it is not essential for the lysis formulation to have the ability to digest RNA in order to carry out the method of the present invention.
[0029] After lysis, the samples are treated again with TFF to remove lytic enzymes, remove DNA fragments, and remove host histone proteins liberated by lysis of the host DNA.
[0030] A particularly unexpected experimental finding was that dissolving DNA alone was not sufficient to completely solve the problem, even when dissolving conditions were fully optimized. Experimental data suggest that residual histones interfere with chromatographic methods, reducing their ability to remove contaminants such as DNA. Removal of histones prior to chromatography enhances the removal of all classes of contaminants, and even more so, of contaminating DNA.
[0031] The second TFF step uses a buffer that exhibits near-physiological conditions, such as a pH of 6.5-7.5 and a sodium chloride concentration of 25-200 mM. Maintenance of near-physiological conditions is believed to be a valuable contributor to the enhancement obtained by the method of the present invention.
[0032] TFF sample preparation often uses buffers that approximate the binding conditions of the following chromatographic methods. Although near-physiological conditions are suitable for AAV capture by affinity chromatography, the method of the present invention reduces the overall contaminant load to such an extent that alternative methods such as cation exchange or anion exchange chromatographic capture can produce high purity AAV without relying on affinity chromatography. This is important considering that commercially available affinity chromatography media have low flow rates, long processing times, and cannot withstand 1.0M NaOH washes. Ion exchanger capture allows the use of chromatographic media that are compatible with high flow rates, high binding capacity, and extended cleaning and disinfection with 1.0M NaOH.
[0033] In one embodiment, the method steps described above are used to prepare a sample for loading onto an affinity chromatography column.
[0034] In another embodiment, the above method steps are used to prepare a sample for loading onto a positively charged chromatography column, such as an anion exchanger. In this case, the sample is diluted after the second TFF step so that the conductivity is low enough to ensure high performance binding of AAV to the column. Also, the pH of the sample may be adjusted to a higher value to better facilitate the differentiation of empty and full capsids. Magnesium and / or calcium salts may be added to modify the selectivity of the empty-full separation. This method may be suitable for the production of research grade full capsids.
[0035] In another embodiment, the method steps described above are used to prepare a sample for loading onto a cation exchanger. A typical preparation for preparing a sample for binding to a cation exchanger involves titrating the pH of the sample down to pH 3.5. This changes the titration state of the amino acid residues on the surface of the capsid protein, making the capsid surface net electropositive in pure water. The positive charge on the surface allows it to bind to the negatively charged surface of the cation exchanger. However, this also has a detrimental effect. Making the capsid surface electropositive induces strong binding of DNA, and if DNA is already bound to the capsid outer surface, the low pH stabilizes the binding. In any case, the low binding pH promotes DNA binding to the capsid outer surface.
[0036] Another aspect of this issue makes it even more problematic: if DNA is bound to the capsid exterior, the excess histone proteins in the system will very likely bind to the capsid exterior-associated DNA. This highlights the value of a second TFF step to remove not only DNA fragments but also histone proteins. In this context, it is important to emphasize that extremely low pH, such as pH 3.5, amplifies the positive charges on not only histone proteins but also other DNA-binding proteins such as transcription factors and ubiquitin.
[0037] The method of the present invention includes another feature to address these possibilities, which also provides a surprising effect. Instead of equilibrating the sample to pH 3.5, the sample is equilibrated to a milder pH of pH 5.0±0.25 in preparation for binding to the cation exchanger. The cation exchanger is also equilibrated under the same conditions and the sample is allowed to bind. After sample binding, the column is re-equilibrated to pH 3.5 and the AAV is eluted with an increasing salt gradient. Experimental data shows that this approach substantially reduces contamination of the AAV fraction eluted from the cation exchanger. This approach removes small contaminants, particularly those in the size range of DNA-binding proteins. This may suggest that histones and other DNA-binding proteins still remaining in the sample after the previous steps of the method of the present invention bind to the cation exchanger when the sample is applied to the column and remain bound there while the AAV is eluted. This is consistent with the known behavior that histone proteins do not elute from cation exchangers in NaCl, but instead require guanidine or NaOH for elution. Whatever the mechanism, it substantially improves the quality of the eluted AAV.
[0038] After the initial cation exchange chromatography step, the AAV is applied to a positively charged chromatography device, such as an anion exchanger, to further extract the DNA and separate empty capsids from full capsids (referring to capsids containing the desired therapeutic DNA plasmid). AAV capsids may be similarly treated after the initial affinity chromatography step.
[0039] Cation exchange chromatography media are widely available commercially with a variety of ligands and in a variety of physical forms. The main distinguishing feature of cation exchangers is that they are negatively charged. Biological species with a sufficient positive charge can bind to the cation exchanger and then be eluted, most commonly by increasing the salt concentration. However, all cation exchangers are multimodal, meaning that electrostatic interactions are only one of the chemical mechanisms that contribute to binding with biomolecules. The two most common cation exchange ligands are carboxyalkane groups, such as carboxymethyl, carboxyethyl, and carboxypropyl, and sulfoalkane groups, such as sulfomethyl, sulfoethyl, and sulfopropyl. Carboxyalkane cation exchange groups contain a carbonyl oxygen atom with two free lone pairs and a carboxyl oxygen atom with three free lone pairs. These lone pairs are hydrogen acceptors, giving these ligands the potential to form hydrogen bonds. Sulfoalkane cation exchange groups contain three oxygen atoms, two of which are uncharged but have two lone pairs of free electrons. The third is negatively charged and has three lone electrons that give the ligand the ability to contribute to hydrogen bonds as a hydrogen donor. Cation exchangers may use alkane-phosphatidic acid residues. Depending on the pH, the residues have either two negatively charged oxygen atoms with three lone pairs each and one uncharged oxygen atom with two lone pairs, or one negatively charged oxygen atom with three lone pairs and two uncharged oxygen atoms with two lone pairs each. Phosphatidic acid-based cation exchangers also have the ability to contribute to metal coordination. Di-carboxy, tri-carboxy, and polycarboxy cation exchange ligands also have the ability to bind metals. All of the above ligands also have various levels of hydrophobicity depending on whether the associated alkane contains one, two, three, or more carbon residues. Some cation exchange ligands also contain hydrophobic rings. Thus, for the purposes of the present invention, a cation exchanger is defined as a chromatographic solid phase that carries a negative charge, regardless of any other chemical reactivity that may be embodied.Cation exchangers are commercially available from several suppliers worldwide.
[0040] The same general logic applies to anion exchange chromatographic media. For the purposes of this invention, anion exchange chromatographic media is defined as a chromatographic solid phase that has a positive charge, regardless of any additional chemical reactivity that may be embodied. The charged nitrogen atom of a weak anion exchanger has one free lone pair of electrons, making it a hydrogen acceptor. A hydrogen atom directly bonded to the nitrogen atom can act as a hydrogen donor. The charged nitrogen atom of a strong anion exchanger has no free lone pair of electrons. The alkane group bonded to the nitrogen atom on the strong anion exchanger and on the weakest anion exchanger provides hydrophobicity. Others have other hydrophobic structures. Some anion exchangers utilize polymer-based ligands that provide other combinations of chemically reactive properties. All anion exchangers are multimodal. Anion exchangers are commercially available from multiple suppliers around the world.
[0041] Ligands for affinity chromatography consist of peptides and proteins and are often antibodies or antibody substructures such as the F(ab)'2 or Fab regions, single light chain derivatives (scFV), or recombinant structures that mimic the specificity of antibodies. As with ion exchangers, many commercial variations are available from suppliers worldwide.
[0042] The process of solid-phase DNA extraction begins when a cell culture harvest or lysate containing AAV is contacted with a positively charged surface(s) under approximately physiological conditions. The sample is contacted with the positively charged surface(s) for approximately 1 minute to 4 hours.
[0043] In an embodiment where the positively charged surface(s) are in the form of particles, the volume ratio of particles to sample may be 0.1%-10%, 1%-5%, 2%-5%, or any higher, lower, or intermediate ratio.
[0044] In one embodiment where the positively charged surface(s) are in the form of particles, the contact time may be from 10 minutes to 240 minutes, or from 20 minutes to 120 minutes, or from 30 minutes to 60 minutes, or any longer, shorter, or intermediate amount of time.
[0045] In one or more embodiments in which the positively charged surface(s) is in the form of a flow-through device, the contact time can be from 1 minute to 60 minutes, or from 2 minutes to 30 minutes, or from 5 minutes to 15 minutes, or any longer, shorter, or intermediate amount of time.
[0046] In some cases, the positively charged particles may be mixed with particles having other chemistries, and experimental data shows that a mixture of positively and negatively charged particles removes more contaminants than the positively charged particles alone.
[0047] DNase treatment may be carried out for 15 minutes to 24 hours, or 30 minutes to 16 hours, or 1 hour to 8 hours, or longer, shorter or intermediate amounts of time. Longer intervals, such as 16 hours to 24 hours, may be preferred, as the particular aim is to achieve as high a degree of DNA lysis as possible.
[0048] The DNase treatment is preferably carried out in the same TFF unit used to concentrate and equilibrate the buffer for DNase treatment. The transmembrane pressure is set to zero and the sample is recirculated through the system after DNase addition and mixed thoroughly. After the digestion process is complete, the TFF buffer is changed to a buffer with a pH of about 5 and a salt concentration of 20 mM to 100 mM. The transmembrane pressure is set to a positive value and TFF is resumed. Most of the enzyme is excluded along with the DNA fragments and most especially the histone proteins.
[0049] The term pH about 5 is understood to mean a pH value in the range of 4.0-6.0, or 4.5-5.5, or 4.75-5.25. The skilled artisan will understand that the lower the pH value, the higher the concentration of salts that may be present in the sample, but still allow AAV to be captured by the cation exchanger. The sample may be diluted at this point in order to increase the binding capacity of the cation exchanger. In general, the visual clarity of the equilibrated sample may be an indication of suitability of the conditions. Turbidity or the appearance of whitish filaments or particles is an indication that the pH is too low.
[0050] Once the AAV particles are loaded onto the cation exchanger, the cation exchanger is re-equilibrated to about pH 3.5±0.5, for example with a buffer containing formic acid, or acetic acid, or glycine, or some combination of these species, at a concentration of 20 mM to 50 mM. The buffer may contain 20 mM to 200 mM NaCl to prevent binding by contaminants that are less electropositive than the AAV capsid. After re-equilibration, the column is eluted with a salt gradient of 1.0 M NaCl or higher. After elution, the column is washed with 1.0 M NaOH, optionally 1 to 3 M NaCl, and 20 mM to 50 mM EDTA.
[0051] There are many commercially available options for DNase enzymes to carry out the methods of the invention. Examples include Endonuclease (Protean), Deoxyribonuclease (Worthington), Saltonase (Blirt), San-HQ and M-San HQ (ArcticZymes), Denarase (C-Lecta), TurboNuclease (Accelagen), Kaneka Endonuclease (Kaneka), DNase (New England Biolabs), and Cryptonase (BIA Separations). Each of these enzymes has characteristic conditions for most efficient digestion of DNA. Some are more tolerant of salt than others. Some are more effective at lower temperatures than others. Some are capable of dissolving not only DNA but also RNA. Those that do not have this capability can be supplemented with RNase enzymes as needed.
[0052] Positively charged particles are commercially available in many forms from many suppliers. Particle-based anion exchange chromatography media are a large group of candidates, where the positive charge can come from various forms and combinations of amine derivatives on the particle surface. Such forms and combinations include primary amine groups, individual residues and polymers, such as polyallylamine and chitosan; secondary amine groups, individual residues and polymers; tertiary amine groups, individual residues and polymers, such as DEAE and DEAE dextran; quaternary amine groups, individual residues and polymers, such as Q, QA and Q or QA dextran, or cholestyramine; individual ligands and polymers that contain primary, secondary and tertiary amine groups. Individual ligands that contain such combinations include immobilized ethylenediamine, which contains primary and secondary amine groups, and tris(2-aminoethyl)amine, whose immobilized form contains primary, secondary and tertiary amine groups. Polymers with mixed amino forms include polyethyleneimine, which has different proportions of primary, secondary and tertiary amines depending on the degree of branching in the polymer. The physical matrix of the particles can be polymeric, silica-based, metal oxide-based, or composites thereof. The particles can be of any size, such as in the range of 0.1 μm to 200 μm. The particles can be non-porous or porous in the range of 0.1 nm to 10 μm. The particles can be spherical, spheroidal, non-spherical, irregular, filamentary, or mixtures thereof.
[0053] Electropositive particles may be blended with other particles having other chemical reactivities. Preliminary experimental data indicates that a combination of electropositive (ethylenediamine) and electronegative (SO3) particles may remove more protein contaminants than the electronegative particles alone. Electropositive particles may be multimodal as described above, where a given species of electropositive particle can interact with contaminants not only through electrostatic interactions but also through additional reactivities such as hydrogen bonding, hydrophobicity, or metal affinity.
[0054] Electropositive flow-through devices are also widely available commercially. Formats such as so-called depth filters are becoming increasingly popular. Others may include simple membrane formats known as membrane adsorption units. Others include so-called hydrogels, columns of packed particles, columns of packed fibers, and devices that include positively charged surfaces in multiple physical forms. The surface chemistry of such flow-through devices may include any of the surface chemistries described for the particles.
[0055] Example 1: Purification of AAV using the method of the present invention First, 5 mL of positively charged particles were added to 300 mL of cell lysate containing AAV serotype 8. The particles were aspherical polymethacrylate particles with a size range of 20 μm to 40 μm and an average pore size of 2 μm, with ethylenediamine immobilized on the surface. The ethylenediamine immobilized on the solid surface is positively charged by having a primary amine and a secondary amine at each residue. The preparation was stirred for 30 min. The particles were removed by centrifugation at 10,000 × g for 10 min and filtration through a 0.45 μm PES membrane.
[0056] The particle-free supernatant was concentrated 14-fold by tangential flow filtration using a 300 kDa molecular weight cutoff membrane and simultaneously buffer exchanged into 50 mM Tris, 0.5 M NaCl, 5 mM magnesium chloride, 1% sucrose, 0.1% poloxamer, pH 8.0.
[0057] Halotolerant DNase was added to a final concentration of 50 units per mL, and the mixture was incubated at room temperature for 16 h. Tangential flow filtration was resumed with the same mechanical unit and the same original membrane in 20 mM HEPES, 30 mM sodium chloride, 1% sucrose, 0.1% poloxamer, pH 7.0.
[0058] The optically clear AAV-containing supernatant was titrated to pH 5.25 by slowly adding 2M acetic acid. A strong cation exchanger (SO3) was equilibrated in 20mM MES, 30mM sodium chloride, 1% sucrose, 0.1% poloxamer, pH 5.25. The equilibrated sample was loaded onto the equilibrated column and washed with equilibration buffer to remove unbound contaminants.
[0059] The cation exchange column was then re-equilibrated in 50 mM formic acid, 30 mM sodium chloride, 1% sucrose, 0.1% poloxamer, pH 3.5. After re-equilibration, the column was eluted with a linear gradient of increasing sodium chloride and washed with 1 M sodium hydroxide, 2 M sodium chloride. The chromatogram is shown in Figure 2. The AAV peak was evaluated by SDS-PAGE (Figure 3).
[0060] Example 2: Purification of AAV using some of the steps of the method of the invention A sample of the same material as described in Example 1 was similarly processed through a second TFF step and then titrated to pH 3.5 by the slow addition of 2M formic acid.
[0061] The same cation exchanger was equilibrated in 50 mM formic acid, 0.2 M sodium chloride, 1% sucrose, 0.1% poloxamer, pH 3.5. The sample was loaded and the column was washed with equilibration buffer before elution with the same linear gradient configuration as described in Example 1. The column was washed with 1 M NaOH, 2 M sodium chloride.
[0062] Figure 3 compares the degree of purification obtained in the two examples. The first three sample lanes show the results of Example 2, where the cation exchange step was performed at pH 3.5. The next three sample lanes show the results of Example 1, where the cation exchanger and sample were initially equilibrated to pH 5.25, the sample was loaded and washed at that pH, and the column was then re-equilibrated to pH 3.5 and eluted at that pH. The results show that the sample equilibrated at pH 5.25 contained fewer contaminants, and the cation exchanger was able to obtain a cleaner AAV fraction. The sample equilibrated at pH 3.5 was more contaminant, and the cation exchange produced a more impure fraction.
[0063] <Example 3> A control experiment using affinity chromatography was performed to demonstrate the potential advantages of using the method of the present invention over other AAV capture methods. An AAV affinity column was equilibrated with 50 mM phosphate, 100 mM NaCl, pH 7.2. The sample was equilibrated to the same pH, filtered, and then loaded onto the column. The column was washed with equilibration buffer and then eluted with a step to 50 mM glycine, pH 3.0. After elution, the column was washed with 25 mM sodium hydroxide.
[0064] The chromatograms are shown in Figure 4. Comparing the chromatograms in Figures 2 and 4 shows that affinity chromatography, like cation exchange chromatography, has problems with binding excess contaminants.
[0065] The results of the SDS-PAGE analysis are shown in Figure 5. Comparing the PAGE gel of Figure 3 with the chromatogram of Figure 5 shows that the method of the present invention using cation exchange chromatography results in better purification than affinity chromatography without the advantages of the method of the present invention.
[0066] Affinity chromatography is generally considered to provide the best capture purification of all chromatographic methods. The performance of the method of the present invention, which allows common purification methods such as cation exchange chromatography to obtain clearly superior purification, emphasizes that the performance of the method of the present invention enhances the purification capacity. It can also be said that this significantly improves the purification performance of affinity chromatography as a capture method, and in some cases, it will allow the purification of at least research grade AAV by performing anion exchange chromatography purification after the initial step of the method, as described in Example 2.
[0067] Example 4: Application of the method to initial capture by affinity chromatography The steps of the invention are followed up to the second TFF step, but without the subsequent steps of lowering the pH and applying the sample to a cation exchanger. Instead, the sample is applied directly to an affinity chromatography column. The column is then washed and eluted as if the enhancement of the invention was not used.
[0068] Example 5: Application of the present invention to initial capture by anion exchange chromatography The steps of the present invention are carried out up to the second TFF step, but the subsequent steps of lowering the pH and applying the sample to the cation exchanger are not carried out. Instead, the sample is diluted to a conductivity (salt concentration) low enough so that AAV binds to the anion exchanger equilibrated to the same conditions. The column is then washed and eluted as in the case without the enhancement of the present invention.
[0069] Example 6: Replacement of positively charged particles with the positively charged inner surface of a flow-through device Any of the above embodiments can be implemented by replacing the positively charged particles with large positively charged surfaces, such as those found in many commercially available filtration media, such as depth filters. The present invention includes the following aspects. <1> 1. A method for reducing the contaminating DNA content of a preparation containing AAV capsid and contaminating DNA, comprising the steps of: (a) performing extraction of DNA using a solid phase carrying a positive charge on its surface to obtain a first fraction, wherein the solid phase is contacted with the preparation at pH 7.0±1.0 and a salt concentration of 10 mM to 200 mM; (b) diafiltering the first fraction by a first tangential flow filtration to obtain a second fraction; (c) treating the second fraction with DNAse; (d) diafiltering the DNAse-treated second fraction obtained in step (c) into a buffer having a pH of 7.0±1.0 and a salt concentration of 10 mM to 20 mM by a second tangential flow filtration to obtain a third fraction; and Optionally, (e) concentrating the third fraction by tangential flow filtration prior to complementary chromatography. <2> the solid phase is in the form of loose bulk particles or a flow-through device; <1> The method according to <3> The tangential flow filtration is carried out using a membrane selected from the group consisting of hollow-fiber membranes, such as single hollow-fiber membranes or bundled membranes, or flat membranes, such as single membranes or stacked or rolled membranes. <1> or <2> The method according to <4> The first filtration is carried out in a buffer formulated to promote DNA digestion by DNAse; <1> ~ <3> 2. The method according to claim 1 . <5> The porosity of the tangential flow filtration membrane is in the range of 10 kDa to 300 kDa, 30 kDa to 300 kDa, 60 kDa to 300 kDa, 100 kDa to 300 kDa, 200 kDa to 300 kDa, or 250 kDa to 300 kDa, and preferably has a molecular weight cutoff of 100 kDa or more. , <3> or <4> The method according to <6> the preparation comprising AAV capsids and contaminating DNA comprises AAV particles selected from the group consisting of AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or other serotypes, such as recombinant serotypes having characteristics of two or more serotypes; <1> ~ <5> 2. The method according to claim 1 . <7> After step (d) or step (e), at least one of the following purification steps is used: <1> ~ <6> 2. The method according to claim 1, (i) a cation exchange chromatography step, or (ii) an affinity chromatography step, or (iii) Anion exchange chromatography step. <8> In the purification step (i), the fraction of step (d) or (e) is loaded onto a cation exchange chromatography material at pH 4-6 (particularly at about pH 5), followed by: re-equilibrating the cation exchange chromatography material to about pH 3.5±0.5; performing elution using a salt gradient; and Then, anion exchange chromatography is performed. will be carried out, <7> The method according to <9> In the purification step (ii), the fraction from step (d) or (e) is loaded onto an affinity chromatography material and, after elution, is subjected to an anion exchange chromatography treatment. <7> The method according to <10> In the purification step (iii), the fraction of step (d) or (e) is subjected to anion exchange chromatography. <7> The method according to
Claims
1. 1. A method for reducing the contaminating DNA content of a preparation containing AAV capsid and contaminating DNA, comprising the steps of: (a) performing extraction of DNA using a solid phase carrying a positive charge on its surface to obtain a first fraction, wherein the solid phase is contacted with the preparation at pH 7.0±1.0 and a salt concentration of 10 mM to 200 mM; (b) diafiltering the first fraction by a first tangential flow filtration to obtain a second fraction; (c) treating the second fraction with DNAse; and (d) diafiltering the DNAse-treated second fraction obtained in step (c) into a buffer having a pH of 7.0±1.0 and a salt concentration of 10 mM to 30 mM by a second tangential flow filtration to obtain a third fraction.
2. The method of claim 1, further comprising, after step (d), (e) concentrating the third fraction by tangential flow filtration, and, after step (e), performing chromatography.
3. 3. The method of claim 1 or claim 2, wherein the solid phase is in the form of loose bulk particles or a flow-through device.
4. 4. The method of claim 1, wherein the tangential flow filtration is performed using a membrane selected from the group consisting of hollow-fiber membranes, such as single hollow-fiber membranes or bundled membranes, or flat membranes, such as single membranes or stacked or wound membranes.
5. The method of any one of claims 1 to 4, wherein the first tangential flow filtration is carried out in a buffer formulated to promote DNA digestion by a DNAse.
6. 6. The method of claim 4 or claim 5, wherein the porosity of the tangential flow filtration membrane is in the range of 10 kDa to 300 kDa, 30 kDa to 300 kDa, 60 kDa to 300 kDa, 100 kDa to 300 kDa, 200 kDa to 300 kDa, or 250 kDa to 300 kDa.
7. The method of any one of claims 1 to 6, wherein the preparation comprising AAV capsid and contaminating DNA comprises AAV particles selected from the group consisting of AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and recombinant serotypes having characteristics of two or more serotypes.
8. The method according to any one of claims 1 to 7, wherein after step (d) or step (e) at least one of the following purification steps is used: (i) a cation exchange chromatography step, or (ii) an affinity chromatography step, or (iii) Anion exchange chromatography step.
9. In the purification step (i), the fraction of step (d) or (e) is loaded onto a cation exchange chromatography material at pH 4-6 (particularly at about pH 5) followed by: re-equilibrating the cation exchange chromatography material to about pH 3.5±0.5; performing elution using a salt gradient; and Then, anion exchange chromatography is performed. The method of claim 8 , wherein
10. 9. The method according to claim 8, wherein in the purification step (ii) the fraction of step (d) or (e) is loaded onto an affinity chromatography material and, after elution, an anion exchange chromatography treatment is performed.
11. 9. The method of claim 8, wherein in the purification step (iii), the fraction of step (d) or (e) is subjected to anion exchange chromatography.
Citation Information
Patent Citations
Improved purification method for recombinant AAV vectors
JP2012529917A
Scalable, high-recovery method for producing high-yield recombinant adeno-associated virus (rAAV) vectors, and recombinant adeno-associated virus (rAAV) vectors produced thereby
JP2019524101A
LARGE-SCALE RECOMBINANT ADENO-ASSOCIATED VIRUS (rAAV) PRODUCTION AND PURIFICATION
WO2002012455A1
Methods of adenovirus purification
WO2003097797A2
AAV vector column purification methods
WO2019006390A1
